Chronic Illness and Inflammation: Conditions such as diabetes, autoimmune disorders, heart disease, and chronic infections significantly reduce glutathione levels
Results of these trials showed GLP-1 agonists have a favorable safety profile, with most side effects being mild and temporary
First improvement at 1 to 2 weeks, significant change by week 4
This work supports the possibility that there may not be any additional direct mRNA transcriptional targets of GLP-1 signaling
Subsequent mass spectrometry analysis identified interacting proteins, with AFG3-like matrix AAA peptidase subunit 2 (AFG3L2), a mitochondrial inner membrane m-AAA protease, highlighted as a key interactor
The aptly named Shotsy was founded by Aja Beckett, whose own GLP-1 weight loss journey inspired her to create tools for others on these medications